BR112022018730A2 - Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformante - Google Patents
Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformanteInfo
- Publication number
- BR112022018730A2 BR112022018730A2 BR112022018730A BR112022018730A BR112022018730A2 BR 112022018730 A2 BR112022018730 A2 BR 112022018730A2 BR 112022018730 A BR112022018730 A BR 112022018730A BR 112022018730 A BR112022018730 A BR 112022018730A BR 112022018730 A2 BR112022018730 A2 BR 112022018730A2
- Authority
- BR
- Brazil
- Prior art keywords
- interleukin
- recombinant
- analog
- nucleic acid
- expression vector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200039476 | 2020-03-31 | ||
| PCT/KR2021/004028 WO2021201615A1 (ko) | 2020-03-31 | 2021-03-31 | 신규한 면역 활성 인터루킨 2 아날로그 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018730A2 true BR112022018730A2 (pt) | 2022-11-01 |
Family
ID=77930406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018730A BR112022018730A2 (pt) | 2020-03-31 | 2021-03-31 | Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformante |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11746137B2 (https=) |
| EP (1) | EP4130027A4 (https=) |
| JP (2) | JP7846627B2 (https=) |
| KR (2) | KR102545250B1 (https=) |
| CN (2) | CN118271419A (https=) |
| AR (1) | AR121713A1 (https=) |
| AU (2) | AU2021202825B2 (https=) |
| BR (1) | BR112022018730A2 (https=) |
| CA (2) | CA3266069A1 (https=) |
| CL (1) | CL2022002562A1 (https=) |
| IL (1) | IL295826B2 (https=) |
| MX (1) | MX2022011893A (https=) |
| NZ (1) | NZ793819A (https=) |
| PE (1) | PE20221759A1 (https=) |
| TW (1) | TWI876021B (https=) |
| WO (1) | WO2021201615A1 (https=) |
| ZA (1) | ZA202209565B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118271419A (zh) * | 2020-03-31 | 2024-07-02 | 韩美药品株式会社 | 新型免疫刺激il-2类似物 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| KR20230095612A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
| KR102445492B1 (ko) * | 2021-12-24 | 2022-09-21 | 엔케이젠 주식회사 | 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법 |
| US20240076343A1 (en) * | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| JP2025527694A (ja) * | 2022-08-23 | 2025-08-22 | マストバイオ株式会社 | Ｉｌ２変異体及びそれを含むタンパク質複合体 |
| KR20250126198A (ko) | 2024-02-15 | 2025-08-25 | 한림대학교 산학협력단 | 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3285989A (en) * | 1987-11-25 | 1989-06-14 | Cetus Corporation | Treatment of infections caused by a primary immunodeficiency with interleukin-2 |
| AU627477B2 (en) * | 1988-07-05 | 1992-08-27 | Amgen, Inc. | Interleukin ii analogs |
| CA2019714A1 (en) | 1989-06-27 | 1990-12-27 | Richard A. Chizzonite | Process for the determination of interleukins |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| CZ20021186A3 (cs) * | 1999-10-04 | 2002-11-13 | Chiron Corporation | Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid |
| DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| US7569215B2 (en) * | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| US20060234205A1 (en) | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| CN1930300A (zh) | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| AU2007201663A1 (en) | 2007-04-16 | 2008-10-30 | Nautilus Biotech | Oral dosage formulations of protease resistant polypeptides |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| CA2860170C (en) * | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| DK2963056T3 (da) | 2013-02-26 | 2020-02-17 | Hanmi Pharm Ind Co Ltd | Insulinanalog og anvendelse deraf |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| CR20160376A (es) | 2014-01-20 | 2016-10-07 | Hanmi Pharm Ind Co Ltd | Insulina de acción prolongada y uso de la misma |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| JP6821560B2 (ja) | 2014-10-21 | 2021-01-27 | サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． | 免疫刺激剤による癌治療 |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| KR20160134989A (ko) * | 2015-05-14 | 2016-11-24 | 순천향대학교 산학협력단 | 인간 인터류킨-2 단백질을 포함하는 약학조성물 |
| CN107266553A (zh) * | 2016-04-08 | 2017-10-20 | 南京康志制药有限公司 | 高效人白细胞介素ⅱ突变体融合蛋白及其应用 |
| JP7422480B2 (ja) * | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| CA3055200A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| CN111201035A (zh) * | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| CN111094356B (zh) * | 2017-09-25 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 一种蛋白质异二聚体及其用途 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2019147837A2 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| CN108503714A (zh) | 2018-04-10 | 2018-09-07 | 浙江科途医学科技有限公司 | 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用 |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| KR20250156190A (ko) * | 2018-06-22 | 2025-10-31 | 큐진 인크. | 인터루킨-2 변이체 및 이의 사용 방법 |
| MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| US11492384B2 (en) * | 2018-09-17 | 2022-11-08 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| CN113316590B (zh) * | 2018-11-16 | 2025-02-28 | 百时美施贵宝公司 | 抗nkg2a抗体及其用途 |
| EP3901167A4 (en) * | 2018-12-21 | 2022-11-16 | Hanmi Pharm. Co., Ltd. | NOVEL IMMUNOSUPRESSIVE INTERLEUKIN 2 |
| CN111944036B (zh) | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| CN114437198A (zh) | 2019-12-17 | 2022-05-06 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| CA3169095A1 (en) | 2020-03-05 | 2021-09-10 | Kenan Christopher GARCIA | Designed il-2 variants |
| CN118271419A (zh) * | 2020-03-31 | 2024-07-02 | 韩美药品株式会社 | 新型免疫刺激il-2类似物 |
-
2021
- 2021-03-31 CN CN202410385677.5A patent/CN118271419A/zh active Pending
- 2021-03-31 JP JP2022559531A patent/JP7846627B2/ja active Active
- 2021-03-31 BR BR112022018730A patent/BR112022018730A2/pt unknown
- 2021-03-31 MX MX2022011893A patent/MX2022011893A/es unknown
- 2021-03-31 TW TW110111922A patent/TWI876021B/zh active
- 2021-03-31 WO PCT/KR2021/004028 patent/WO2021201615A1/ko not_active Ceased
- 2021-03-31 IL IL295826A patent/IL295826B2/en unknown
- 2021-03-31 PE PE2022001948A patent/PE20221759A1/es unknown
- 2021-03-31 CA CA3266069A patent/CA3266069A1/en active Pending
- 2021-03-31 CN CN202180025732.4A patent/CN115427437B/zh active Active
- 2021-03-31 NZ NZ793819A patent/NZ793819A/en unknown
- 2021-03-31 EP EP21781220.5A patent/EP4130027A4/en active Pending
- 2021-03-31 US US17/915,808 patent/US11746137B2/en active Active
- 2021-03-31 CA CA3169564A patent/CA3169564C/en active Active
- 2021-03-31 AU AU2021202825A patent/AU2021202825B2/en active Active
- 2021-03-31 KR KR1020210042319A patent/KR102545250B1/ko active Active
- 2021-03-31 AR ARP210100815A patent/AR121713A1/es unknown
-
2022
- 2022-06-02 AU AU2022203841A patent/AU2022203841A1/en not_active Abandoned
- 2022-08-26 ZA ZA2022/09565A patent/ZA202209565B/en unknown
- 2022-09-21 CL CL2022002562A patent/CL2022002562A1/es unknown
-
2023
- 2023-06-09 KR KR1020230074093A patent/KR102946368B1/ko active Active
- 2023-07-10 US US18/349,656 patent/US12415842B2/en active Active
- 2023-11-30 JP JP2023202447A patent/JP2024041747A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018730A2 (pt) | Análogo de interleucina-2, ácido nucleico isolado, vetor de expressão recombinante e transformante | |
| BR112021012240A2 (pt) | Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich | |
| MX2021006970A (es) | Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina. | |
| BR112017022298A2 (pt) | geranilgeranil pirofosfato sintase | |
| NZ629394A (en) | Synthetic brassica-derived chloroplast transit peptides | |
| BR112019000352A2 (pt) | material de interface térmica do tipo gel | |
| UA130422C2 (uk) | Варіант та ізоформа антитіла зі зниженою біологічною активністю | |
| MX2022016532A (es) | Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos. | |
| BR112017018251A2 (pt) | vetores retrovirais e lentivirais | |
| BR112017013274A2 (pt) | polipeptídeo e imunomodulação | |
| EA201790934A1 (ru) | ВАРИАНТЫ ИНТЕРФЕРОНА α2b | |
| BR112017011271A2 (pt) | composição, polipeptídeo isolado, aditivo de ração animal, ração animal, métodos de melhoria de um ou mais parâmetros de desempenho de um animal, de solubilização de xilose de material à base de plantas, de liberação de amido de material à base de plantas, de melhoria do valor nutricional de uma ração animal, de preparação de uma ração animal e de produção do polipeptídeo, uso de uma composição, polinucleotídeo, construto de ácido nucleico ou vetor de expressão, e, célula hospedeira recombinante. | |
| BR112019005637A2 (pt) | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso | |
| BR112017020308A2 (pt) | udp-glicosiltransferases | |
| MY206268A (en) | Modified s1 subunit of the coronavirus spike protein | |
| BR112021018734A2 (pt) | Receptores de células t e métodos de uso destes | |
| BR112016030950A2 (pt) | polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. | |
| EA202190240A1 (ru) | Варианты рекомбинантного белка | |
| BR112014030440A8 (pt) | método para preparar um alqueno monoinsaturado | |
| PH12016500251B1 (en) | Rail fastening system | |
| BR112021017486A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| MY198897A (en) | Process for the preparation of methyl mercaptan | |
| BR112012011598A2 (pt) | polipeptídeos de haemophilus parasuis e métodos de uso | |
| BR112022010757A2 (pt) | Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib. | |
| MX2021007354A (es) | Polipeptidos con actividad fitasica. |